Ticarcillin

Summary

Ticarcillin (CHEMBL1449) is an approved small-molecule antibacterial drug (ATC J01CA13); indicated across 4 conditions including bacterial infectious disease and osteomyelitis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CA13
• Indications: 4 conditions
• Chemistry: 384.4 Da · C15H16N2O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1449
Name	Ticarcillin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	36921
ChEBI	CHEBI:9587
ATC	J01CA13
Molecular formula	C15H16N2O6S2
Molecular weight	384.4
InChIKey	OHKOGUYZJXTSFX-KZFFXBSXSA-N

SMILES: CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CSC=C3)C(=O)O)C(=O)O)C

IUPAC name: (2S,5R,6R)-6-[[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A penicillin compound having a 6β-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.

Pharmacological roles (ChEBI): antibacterial drug.

Also known as: Ticarcilina, Ticarcillin, Ticarcilline, ticarcillin, TICARCILLINE, TICARCILLIN

Parent form; salt/anhydrous children: CHEMBL1200855, CHEMBL3765148, CHEMBL3989647

Patent coverage: 7,203 distinct patent families (27,580 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin G/H synthase 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

4 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
osteomyelitis	0	MONDO:0005246	EFO:0003102

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).